Seattle Genetics to Present at Credit Suisse Healthcare Conference
Credit Suisse 2012 Healthcare Conference
BOTHELL, Wash. -- November 09, 2012
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will
present at the upcoming Credit Suisse 2012 Healthcare Conference in Phoenix,
Arizona. The presentation is scheduled for Thursday, November 15, at 2:30 p.m.
Mountain time. It will be webcast live and available for replay from Seattle
Genetics’ website at www.seattlegenetics.com in the Investors and News
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development and
commercialization of monoclonal antibody-based therapies for the treatment of
cancer. The U.S. Food and Drug Administration granted accelerated approval of
ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in
collaboration with Millennium: The Takeda Oncology Company. In addition,
Seattle Genetics has three other clinical-stage antibody-drug conjugate (ADC)
programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations
for its ADC technology with a number of leading biotechnology and
pharmaceutical companies, including Abbott, Agensys (an affiliate of
Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech,
GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC
co-development agreements with Agensys and Genmab. More information can be
found at www.seattlegenetics.com.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
Press spacebar to pause and continue. Press esc to stop.